Mar 15th 2013 - Edison Investment Research today published a report on CytRx Corporation entitled "2013 Catalysts In View". In summary, the report says:
This year could be transformative for CytRx as it delivers important clinical datapoints, regulatory milestones and Phase III starts for its cancer pipeline. Major value inflection points include FDA agreement on the aldoxorubicin pivotal study in second-line soft tissue sarcoma (STS), aldoxorubicin Phase II data in first-line STS and tamibarotene Phase II results in advanced lung cancer. We value the company at $120m, or $4.00 per share, which could rise to $180m, or $5.80 per share, following positive clinical data.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »